Bio Solution Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.94, indicating a relatively balanced mix of debt and equity financing. Despite a current ratio of 0.57, which suggests potential liquidity constraints, the firm maintains a cash and equivalents balance of 11,882,795,470 KRW. However, the negative net cash position after subtracting total debt raises concerns about short-term liquidity. Profitability metrics show a return on equity (ROE) of 0.85% and a return on assets (ROA) of 0.4%, both of which are below the industry median for pharmaceutical firms. The operating margin is 3.5%, and the net profit margin is 1.8%, indicating that the company is generating modest returns relative to its revenue. The company's revenue is concentrated in a few key markets, with South Korea accounting for the majority of its sales. There is limited geographic diversification, which increases exposure to local economic and regulatory risks. The firm has not disclosed segment-specific revenue figures, making it difficult to assess the performance of individual product lines or therapeutic areas. Looking ahead, the company is expected to see a 32% increase in revenue in the current fiscal year, based on analyst estimates. However, the operating income is projected to decline, reflecting ongoing R&D and capital expenditures. The free cash flow of 1,718,762,310 KRW suggests the company is generating positive cash from operations after capital spending, but the negative operating cash flow of -1,311,613,030 KRW indicates that working capital requirements are outpacing cash inflows. The risk assessment highlights medium liquidity risk and low dilution risk. The company has not issued new shares recently, and there is no indication of imminent dilution from shelf or ATM offerings. However, the negative net cash position and the high level of long-term debt (30,024,137,010 KRW) suggest that the company may need to raise additional capital in the near term. Recent filings and transcripts indicate that the company is focusing on expanding its pipeline in oncology and autoimmune diseases. The firm has also been investing in manufacturing capabilities to support future product launches. There are no major regulatory or legal issues currently affecting the company.